Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline
CK Life Sciences, a unit of Li Ka-shing-backed CK Group, plans to bring its cancer vaccine candidates to mainland China through a “fast track” channel as Beijing moves to accelerate early-stage drug development. “We are planning to run investigator-initiated trials [IITs], hopefully, in the next year,” CK Life Sciences’ vice-president and chief scientific officer Dr Melvin Toh Kean-meng said in a recent interview. His comments came as CK Life Sciences set up Sequencio Therapeutics in Hong Kong...المصدر: South China Morning Post | Source: South China Morning Post
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة South China Morning Post. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by South China Morning Post. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
